查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1987540

一氧化氮吸入市場規模、佔有率、趨勢和預測：按應用和地區分類，2026-2034年

Inhaled Nitric Oxide Market Size, Share, Trends and Forecast by Application and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2025年全球吸入式一氧化氮市場規模為10.594億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以5.65%的複合年成長率成長，到2034年達到17.373億美元。目前，北美市場佔據主導地位，預計2025年市佔率將超過77.7%。吸入式一氧化氮市場佔有率的擴大，得益於臨床指南的日益普及，這些指南支持在新生兒加護病房（NICU）廣泛使用吸入式一氧化氮，以及對旨在改善治療方法和患者預後的醫療技術投入的增加。

新生兒併發症發生率的不斷上升正在推動市場成長。醫院和醫護人員正在使用吸入一氧化氮作為治療方法新生兒缺氧性呼吸衰竭和急性呼吸窘迫症候群（ARDS）患者的重要手段。慢性阻塞性肺病（COPD）和其他肺部疾病發生率的上升進一步刺激了吸入一氧化氮的需求。此外，藥物輸送系統的進步提高了吸入一氧化氮療法的效率和可及性。同時，醫療基礎設施和研發投入的增加也促進了創新，並拓展了其醫療應用。監管部門的核准和有利的醫療政策正在推動其應用，尤其是在已開發地區。

由於多種因素，美國正崛起為吸入式一氧化氮市場的重要區域。呼吸系統疾病、新生兒併發症和肺動脈高壓的日益普遍，為吸入式一氧化氮市場創造了有利前景。根據美國政府官方網站公佈的數據，截至2025年2月，美國將有6.5%的人口感染呼吸道融合細胞病毒（RSV）。醫院正在使用吸入式一氧化氮治療新生兒缺氧性呼吸衰竭和急性呼吸窘迫症候群（ARDS）患者。先進的醫療基礎設施和對醫學研發的積極投入正在推動創新，從而改善藥物輸送系統並擴大治療應用。此外，大型製藥企業的進入也加速了產品開發和上市速度。在人口老化和公眾呼吸系統健康意識不斷提高的背景下，美國各醫療機構對吸入式一氧化氮的需求持續成長。

吸入式一氧化氮市場的發展趨勢：

新生兒呼吸系統疾病發生率增加

新生兒呼吸系統疾病及其併發症的日益增加正在推動市場成長。許多早產兒患有缺氧性呼吸衰竭和持續性肺動脈高壓，吸入一氧化氮可以改善氧合水平，並有助於減少體外膜氧合（ECMO）等侵入性治療的需求。根據美國國立衛生研究院（NIH）統計，全球五歲以下兒童下呼吸道感染疾病達3780萬例，死亡501910例，並造成4480萬失能調整後存活年（DALYs）的損失。隨著全球整體早產兒數量的增加，醫院和新生兒加護病房（NICU）越來越依賴這種療法來減輕併發症。監管機構的核准和臨床指南的製定進一步促進了其在新生兒加護病房的廣泛應用。此外，持續的研發工作正在探索吸入一氧化氮在治療其他新生兒疾病方面的新應用，從而擴大其應用範圍。隨著對醫療保健的大量投資和新生兒護理的改進，對吸入一氧化氮的需求不斷增加，它已成為治療方法新生兒呼吸系統疾病的重要方法。

人口老化的過程

人口老化對市場產生了正面影響。老年人更容易患高血壓、動脈硬化、周邊動脈疾病、心臟衰竭和血栓症，這些疾病都需要吸入一氧化氮進行血管擴張。根據 2024 年 MDPI 報告，心臟衰竭性肺病 (COPD)、肺動脈高壓和急性呼吸窘迫症候群 (ARDS) 等疾病，這些疾病需要有效的氧氣療法。吸入一氧化氮有助於改善氧氣流量和降低肺動脈壓力，使其成為老年患者的重要治療方法。隨著預期壽命的延長，醫療保健系統越來越重視先進的呼吸護理，導致醫院和長期照護機構擴大採用吸入一氧化氮。隨著需要呼吸支持的老年人數量不斷成長，對吸入一氧化氮的需求也隨之增加。

加大對先進醫療基礎設施的投資

對先進醫療基礎設施的投入不斷增加，推動了吸入式一氧化氮市場的成長。根據美國國際貿易管理局 (ITA) 網站發布的資訊，2024 年，印度政府新建了五家全印度醫學科學研究所 (AIIMS)，並在全國範圍內實施了共計 202 個醫療基礎設施發展項目，以促進醫療技術的進步。在設備齊全的醫院、專業的新生兒護理病房和現代化的重症監護設施中，吸入式一氧化氮被廣泛用於治療缺氧性呼吸衰竭、肺動脈高壓和急性呼吸窘迫症候群(ARDS) 等疾病。先進醫療設備的普及提高了吸入式一氧化氮療法的療效，使新生兒和成人呼吸系統疾病患者都能獲得更有效的治療。對醫療技術和研發活動的積極投入，進一步改善了治療方法，並帶來了更好的患者預後。監管機構也支持創新，鼓勵開發更先進的吸入裝置和藥物輸送系統。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：全球一氧化氮吸入市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依應用領域分類

  • 新生兒呼吸治療
  • 慢性阻塞性肺病（COPD）
  • 急性呼吸窘迫症候群（ARDS）
  • 其他

第7章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第8章 SWOT 分析

第9章：價值鏈分析

第10章：波特五力分析

第11章：價格分析

第12章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Air Liquide SA
    • Bellerophon Therapeutics
    • Beyond Air Inc.
    • Linde plc
    • Mallinckrodt plc
    • Merck KGaA
    • Novoteris LLC
    • Nu-Med Plus
    • VERO Biotech LLC
Product Code: SR112026A4100

The global inhaled nitric oxide market size was valued at USD 1,059.4 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 1,737.3 Million by 2034, exhibiting a CAGR of 5.65% from 2026-2034. North America currently dominates the market, holding a market share of over 77.7% in 2025. The inhaled nitric oxide market share is expanding, driven by the rising adoption of clinical guidelines that support the widespread utilization of inhaled nitric oxide in neonatal intensive care units (NICUs), along with increasing investments in healthcare technology to enhance treatment methods, leading to better patient outcomes.

The increasing cases of neonatal complications are fueling the market growth. Hospitals and healthcare providers use inhaled nitric oxide as a critical treatment for newborns with hypoxic respiratory failure and patients suffering from acute respiratory distress syndrome (ARDS) . The rising incidence of chronic obstructive pulmonary disease (COPD) and other lung disorders is further catalyzing the demand for inhaled nitric oxide. Besides this, advancements in drug delivery systems improve the efficiency and accessibility of inhaled nitric oxide therapy. Moreover, the growing investments in healthcare infrastructure and research are encouraging innovations, expanding its medical applications. Regulatory approvals and favorable healthcare policies support wider adoption, especially in developed regions.

The United States has emerged as a major region in the inhaled nitric oxide market owing to many factors. The increasing prevalence of respiratory diseases, neonatal complications, and pulmonary hypertension is offering a favorable inhaled nitric oxide market outlook. According to the data published on the official website of the United States government, as of February 2025, 6.5% of people in the US were suffering from respiratory syncytial virus (RSV) . Hospitals rely on inhaled nitric oxide to treat newborns with hypoxic respiratory failure and patients with ARDS. Advanced healthcare infrastructure and strong investments in medical research and development (R&D) activities promote innovations, improving drug delivery systems and expanding therapeutic applications. Additionally, the presence of major pharmaceutical companies accelerates product development and availability. With a growing elderly population and rising awareness among the masses about respiratory care, the demand for inhaled nitric oxide in the US continues to strengthen across various healthcare settings.

INHALED NITRIC OXIDE MARKET TRENDS:

Growing prevalence of respiratory diseases in newborns

The increasing prevalence of respiratory and other subsequent diseases in newborns is propelling the market growth. Many premature babies suffer from hypoxic respiratory failure and persistent pulmonary hypertension, conditions where inhaled nitric oxide helps to improve oxygen levels and reduce the need for invasive procedures like extracorporeal membrane oxygenation (ECMO). According to the NIH, lower respiratory infections in children under five accounted for 37.8 Million cases, 501,910 deaths, and 44.8 Million disability-adjusted life years worldwide. As preterm births rise globally, hospitals and neonatal care units rely more on this therapy to reduce complications. Regulatory approvals and clinical guidelines further support its widespread use in NICUs. Additionally, ongoing R&D efforts are assisting in exploring new applications for inhaled nitric oxide in treating other neonatal conditions, increasing its adoption. With high healthcare investments and enhanced neonatal care, the demand for inhaled nitric oxide is rising, making it a crucial treatment for newborn respiratory disorders.

Rising geriatric population

The growing geriatric population is positively influencing the market. Older adults are more susceptible to hypertension, atherosclerosis, peripheral artery disease, heart failure, and thrombosis, all of which require inhaled nitric oxide for vasodilation. As per a 2024 MDPI report, heart failure prevalence rose with age, annually affecting about 1% of individuals under 55 and exceeding 10% in those over 70. The elderly population is also relatively more prone to conditions like COPD, pulmonary hypertension, and ARDS, creating the need for effective oxygen therapy. Inhaled nitric oxide helps to improve oxygen flow and reduce lung pressure, making it a crucial treatment for elderly patients. As life expectancy rises, healthcare systems focus on advanced respiratory treatments, leading to higher adoption of inhaled nitric oxide in hospitals and long-term care facilities. With the increasing number of elderly individuals requiring respiratory support, the demand for inhaled nitric oxide is rising.

Increasing investments in advanced healthcare infrastructure

The rising investments in advanced healthcare infrastructure are fueling the inhaled nitric oxide market growth. According to the information provided on the official website of the International Trade Administration (ITA), in 2024, the Indian Government launched five new All India Institute of Medical Sciences (AIIMS) centers and introduced a total of 202 healthcare infrastructure initiatives throughout the country to promote progress in healthcare technologies. Well-equipped hospitals, specialized neonatal care units, and modern intensive care facilities widely employ inhaled nitric oxide for treating conditions like hypoxic respiratory failure, pulmonary hypertension, and ARDS. The availability of advanced medical equipment improves the efficiency of inhaled nitric oxide therapy, making it more effective for both newborns and adults with respiratory disorders. Strong investments in healthcare technology and R&D activities further enhance treatment methods, leading to better patient outcomes. Regulatory bodies also support innovations, encouraging the development of improved inhalation devices and drug delivery systems.

INHALED NITRIC OXIDE INDUSTRY SEGMENTATION:

Analysis by Application:

  • Neonatal Respiratory Treatment
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Acute Respiratory Distress Syndrome (ARDS)
  • Others

Neonatal respiratory treatment held 86.1% of the market share in 2025. It is the primary therapy for newborns with hypoxic respiratory failure and persistent pulmonary hypertension. Inhaled nitric oxide helps to improve oxygen levels by relaxing blood vessels in the lungs, reducing the need for invasive procedures like ECMO. Hospitals widely adopt this treatment due to its effectiveness and safety in managing neonatal respiratory distress. The increasing number of preterm births and rising cases of neonatal lung disorders further drive the demand for inhaled nitric oxide. Regulatory approvals and clinical guidelines support the employment of inhaled nitric oxide in neonatal care, ensuring its availability in healthcare settings. Additionally, ongoing research focuses on expanding its applications in premature infants, increasing its market dominance. With advancements in neonatal care and better access to specialized treatments, the requirement for inhaled nitric oxide in neonatal respiratory therapy is growing, keeping it at the forefront of the market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for 77.7%, enjoys the leading position in the market. The region is noted for its strong healthcare infrastructure, high prevalence of respiratory diseases, and increasing neonatal complications. The region has a well-developed hospital network that widely adopts inhaled nitric oxide therapy for conditions like hypoxic respiratory failure in newborns and ARDS in adults. The rising cases of COPD and pulmonary hypertension further drive the demand for inhaled nitric oxide. As per the information provided on the official website of the National Library of Medicine, as of April 2024, a sum of 29,445 male and 14,693 female cases of COPD were registered in workers in Canada. The ongoing R&D efforts by pharmaceutical companies contribute to continuous innovations in drug delivery systems and treatment protocols. Favorable regulatory policies and approvals from government agencies are supporting the market growth by ensuring safety. Additionally, high healthcare spending and reimbursement policies make inhaled nitric oxide treatments more available to patients.

KEY REGIONAL TAKEAWAYS:

UNITED STATES INHALED NITRIC OXIDE MARKET ANALYSIS

The United States holds 93.20% of the market share in North America. The market in the United States is significantly driven by the increasing incidence of neonatal hypoxic respiratory failure, pulmonary hypertension (PAH), and ARDS. The Pulmonary Hypertension Association Registry anticipated that in 2022, the mortality rates for patients with PAH at 1, 2, and 3 years were 8%, 16%, and 21%, respectively, in the US. In 2011, the estimated prevalence of PAH was 109 per Million in commercially insured individuals and 451 per Million in Medicare patients, whereas in 2022, projections suggested approximately 40,000 adult PAH patients in the country. The high adoption of inhaled nitric oxide therapy in NICUs and post-cardiac surgery patients is driving the demand. The market is witnessing significant innovations, with companies developing advanced inhaled nitric oxide delivery systems that eliminate bulky gas cylinders, improving hospital efficiency and patient care. Regulatory approvals for portable and home-use inhaled nitric oxide devices are expanding accessibility beyond hospital settings. Increased competition is accelerating advancements in cost-effective and safer inhaled nitric oxide therapies. Moreover, the rising focus on digital health integration and precision dosing is supporting the market growth.

EUROPE INHALED NITRIC OXIDE MARKET ANALYSIS

The European market is expanding due to the strong healthcare infrastructure, rising cases of chronic lung diseases, and increasing preterm births requiring respiratory support. According to the European Environment Agency, in 2021, respiratory diseases were the third leading cause of death in its member countries, accounting for approximately 420,000 fatalities annually, with over 60% due to chronic respiratory diseases (CRDs). Environmental factors contributed to one-third of these deaths, nearly 80,000 preventable fatalities each year. Air pollution (14%), extreme temperatures (11%), occupational exposures (8%), and second-hand smoke (3%) were major risk causes. Regulatory frameworks, including CE Mark approvals, ensure high standards for inhaled nitric oxide therapy, promoting its use in hospitals and specialized clinics. Research into inhaled nitric oxide's role in treating PAH and post-operative care is driving the demand. Increased investments in precision medicine and artificial intelligence (AI)-based monitoring systems are improving therapy efficiency. Collaborations between healthcare institutions and pharmaceutical companies are leading to innovations.

ASIA-PACIFIC INHALED NITRIC OXIDE MARKET ANALYSIS

The Asia-Pacific market is seeing a rapid rise attributed to increasing healthcare investments, rising neonatal respiratory disorders, and the growing awareness about advanced respiratory treatments. According to the India Brand Equity Foundation, India's healthcare sector was valued at USD 372 Billion in 2024, employing 7.5 Million people. Public healthcare spending reached 1.9% of GDP in FY24, while the hospital market, worth USD 98.98 Billion in 2023, is set to attain USD 193.59 Billion by 2032. China, Japan, and India are leading in inhaled nitric oxide adoption, driven by government initiatives to improve neonatal and pulmonary care. The expansion of tertiary hospitals and research centers is catalyzing the demand for advanced inhaled nitric oxide delivery systems. Industry leaders are investing in localized production and cost-effective solutions to refine market penetration.

LATIN AMERICA INHALED NITRIC OXIDE MARKET ANALYSIS

In Latin America, the market is experiencing growth on account of the improved healthcare infrastructure, neonatal care awareness, and rising respiratory illness cases. An NIH review of 3,627 ARDS patients in 32 studies found 52% mortality rate in Latin America in 2023, varying by study type and region. Brazil and Mexico lead inhaled nitric oxide adoption through government pediatric and critical care initiatives. Investments in cost-effective respiratory therapies are enhancing local production and distribution. Portable inhaled nitric oxide delivery systems are expanding access in remote areas. Moreover, private-sector investments and worldwide collaborations are improving inhaled nitric oxide availability. Research into inhaled nitric oxide for respiratory infections and pulmonary conditions is further creating new market opportunities across Latin America.

MIDDLE EAST AND AFRICA INHALED NITRIC OXIDE MARKET ANALYSIS

The market in the Middle East and Africa is experiencing growth driven by rising investments in neonatal and critical care, particularly in GCC countries. Increasing respiratory diseases, premature births, and ARDS cases are driving hospital demand for inhaled nitric oxide therapy. During Q1 2024, the Dubai Health Authority (DHA) reported a 9% increase in healthcare settings and a 7% rise in professionals, licensing 12,319 specialists and 150 centers, totaling 5,020 facilities and 59,509 healthcare workers. Partnerships with international healthcare providers are promoting inhaled nitric oxide technology adoption.

COMPETITIVE LANDSCAPE:

Key players work on developing efficient solutions to meet the high inhaled nitric oxide market demand. They are investing in R&D activities to improve drug delivery systems and expand the medical applications of inhaled nitric oxide. They focus on creating modern inhalation devices that enhance treatment efficiency and patient outcomes. Strategic partnerships with healthcare providers and research institutions help to strengthen distribution networks and accelerate innovations. Regulatory approvals and compliance with safety standards ensure widespread adoption in hospitals and clinics. Key companies also wager on clinical trials to explore new therapeutic uses, increasing market potential. Marketing efforts and awareness campaigns educate healthcare professionals on the benefits of inhaled nitric oxide therapy, driving the demand. Additionally, broadening production capabilities and improving supply chain efficiency are making treatments more accessible. For instance, in February 2024, Third Pole Therapeutics reported the successful conclusion of a preliminary feasibility study for eNOfit, a portable delivery system for inhaled nitric oxide aimed at treating pulmonary hypertension linked to interstitial lung disease. The two-pound appliance enabled use at home and while on the go. This achievement promoted clinical trials and activated the final financing of Third Pole's USD 32 Million Series B funding round .

The report provides a comprehensive analysis of the competitive landscape in the inhaled nitric oxide market with detailed profiles of all major companies, including:

  • Air Liquide S.A
  • Bellerophon Therapeutics
  • Beyond Air Inc.
  • Linde plc
  • Mallinckrodt plc
  • Merck KGaA
  • Novoteris LLC
  • Nu-Med Plus
  • VERO Biotech LLC

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the inhaled nitric oxide market?

2. What is the future outlook of inhaled nitric oxide market?

3. What are the key factors driving the inhaled nitric oxide market?

4. 4. Which region accounts for the largest inhaled nitric oxide market share?

5. Which are the leading companies in the global inhaled nitric oxide market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Inhaled Nitric Oxide Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Application

  • 6.1 Neonatal Respiratory Treatment
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Chronic Obstructive Pulmonary Disease (COPD)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Acute Respiratory Distress Syndrome (ARDS)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 United States
      • 7.1.1.1 Market Trends
      • 7.1.1.2 Market Forecast
    • 7.1.2 Canada
      • 7.1.2.1 Market Trends
      • 7.1.2.2 Market Forecast
  • 7.2 Asia-Pacific
    • 7.2.1 China
      • 7.2.1.1 Market Trends
      • 7.2.1.2 Market Forecast
    • 7.2.2 Japan
      • 7.2.2.1 Market Trends
      • 7.2.2.2 Market Forecast
    • 7.2.3 India
      • 7.2.3.1 Market Trends
      • 7.2.3.2 Market Forecast
    • 7.2.4 South Korea
      • 7.2.4.1 Market Trends
      • 7.2.4.2 Market Forecast
    • 7.2.5 Australia
      • 7.2.5.1 Market Trends
      • 7.2.5.2 Market Forecast
    • 7.2.6 Indonesia
      • 7.2.6.1 Market Trends
      • 7.2.6.2 Market Forecast
    • 7.2.7 Others
      • 7.2.7.1 Market Trends
      • 7.2.7.2 Market Forecast
  • 7.3 Europe
    • 7.3.1 Germany
      • 7.3.1.1 Market Trends
      • 7.3.1.2 Market Forecast
    • 7.3.2 France
      • 7.3.2.1 Market Trends
      • 7.3.2.2 Market Forecast
    • 7.3.3 United Kingdom
      • 7.3.3.1 Market Trends
      • 7.3.3.2 Market Forecast
    • 7.3.4 Italy
      • 7.3.4.1 Market Trends
      • 7.3.4.2 Market Forecast
    • 7.3.5 Spain
      • 7.3.5.1 Market Trends
      • 7.3.5.2 Market Forecast
    • 7.3.6 Russia
      • 7.3.6.1 Market Trends
      • 7.3.6.2 Market Forecast
    • 7.3.7 Others
      • 7.3.7.1 Market Trends
      • 7.3.7.2 Market Forecast
  • 7.4 Latin America
    • 7.4.1 Brazil
      • 7.4.1.1 Market Trends
      • 7.4.1.2 Market Forecast
    • 7.4.2 Mexico
      • 7.4.2.1 Market Trends
      • 7.4.2.2 Market Forecast
    • 7.4.3 Others
      • 7.4.3.1 Market Trends
      • 7.4.3.2 Market Forecast
  • 7.5 Middle East and Africa
    • 7.5.1 Market Trends
    • 7.5.2 Market Breakup by Country
    • 7.5.3 Market Forecast

8 SWOT Analysis

  • 8.1 Overview
  • 8.2 Strengths
  • 8.3 Weaknesses
  • 8.4 Opportunities
  • 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

  • 10.1 Overview
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Degree of Competition
  • 10.5 Threat of New Entrants
  • 10.6 Threat of Substitutes

11 Price Analysis

12 Competitive Landscape

  • 12.1 Market Structure
  • 12.2 Key Players
  • 12.3 Profiles of Key Players
    • 12.3.1 Air Liquide S.A
      • 12.3.1.1 Company Overview
      • 12.3.1.2 Product Portfolio
      • 12.3.1.3 Financials
      • 12.3.1.4 SWOT Analysis
    • 12.3.2 Bellerophon Therapeutics
      • 12.3.2.1 Company Overview
      • 12.3.2.2 Product Portfolio
      • 12.3.2.3 Financials
    • 12.3.3 Beyond Air Inc.
      • 12.3.3.1 Company Overview
      • 12.3.3.2 Product Portfolio
      • 12.3.3.3 Financials
    • 12.3.4 Linde plc
      • 12.3.4.1 Company Overview
      • 12.3.4.2 Product Portfolio
      • 12.3.4.3 Financials
    • 12.3.5 Mallinckrodt plc
      • 12.3.5.1 Company Overview
      • 12.3.5.2 Product Portfolio
      • 12.3.5.3 Financials
    • 12.3.6 Merck KGaA
      • 12.3.6.1 Company Overview
      • 12.3.6.2 Product Portfolio
      • 12.3.6.3 Financials
      • 12.3.6.4 SWOT Analysis
    • 12.3.7 Novoteris LLC
      • 12.3.7.1 Company Overview
      • 12.3.7.2 Product Portfolio
    • 12.3.8 Nu-Med Plus
      • 12.3.8.1 Company Overview
      • 12.3.8.2 Product Portfolio
      • 12.3.8.3 Financials
    • 12.3.9 VERO Biotech LLC
      • 12.3.9.1 Company Overview
      • 12.3.9.2 Product Portfolio

List of Figures

  • Figure 1: Global: Inhaled Nitric Oxide Market: Major Drivers and Challenges
  • Figure 2: Global: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Inhaled Nitric Oxide Market: Breakup by Application (in %), 2025
  • Figure 5: Global: Inhaled Nitric Oxide Market: Breakup by Region (in %), 2025
  • Figure 6: Global: Inhaled Nitric Oxide (Neonatal Respiratory Treatment) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 7: Global: Inhaled Nitric Oxide (Neonatal Respiratory Treatment) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 8: Global: Inhaled Nitric Oxide (Chronic Obstructive Pulmonary Disease (COPD)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Inhaled Nitric Oxide (Chronic Obstructive Pulmonary Disease (COPD)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Inhaled Nitric Oxide (Acute Respiratory Distress Syndrome (ARDS)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Inhaled Nitric Oxide (Acute Respiratory Distress Syndrome (ARDS)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Inhaled Nitric Oxide (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Inhaled Nitric Oxide (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: North America: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: North America: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: United States: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: United States: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Canada: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Canada: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Asia-Pacific: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Asia-Pacific: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: China: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: China: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Japan: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Japan: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: India: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: India: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: South Korea: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: South Korea: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Australia: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Australia: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Indonesia: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Indonesia: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Others: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Others: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Europe: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Europe: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Germany: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Germany: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: France: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: France: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: United Kingdom: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: United Kingdom: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Italy: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Italy: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Spain: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Spain: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Russia: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Russia: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Others: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Others: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Latin America: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Latin America: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Brazil: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Brazil: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Mexico: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Mexico: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Others: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Others: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Middle East and Africa: Inhaled Nitric Oxide Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Middle East and Africa: Inhaled Nitric Oxide Market: Breakup by Country (in %), 2025
  • Figure 62: Middle East and Africa: Inhaled Nitric Oxide Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Global: Inhaled Nitric Oxide Industry: SWOT Analysis
  • Figure 64: Global: Inhaled Nitric Oxide Industry: Value Chain Analysis
  • Figure 65: Global: Inhaled Nitric Oxide Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Inhaled Nitric Oxide Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Inhaled Nitric Oxide Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 3: Global: Inhaled Nitric Oxide Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 4: Global: Inhaled Nitric Oxide Market: Competitive Structure
  • Table 5: Global: Inhaled Nitric Oxide Market: Key Players